| Autor: |
Othus, Megan, Thomas, Ian, Wang, Xu, Ariti, Cono, Mehta, Priyanka, Sydenham, Mia, Hills, Robert K., Burnett, Alan K., Nand, Sucha, Assouline, Sarit, Michaelis, Laura C., Erba, Harry P., Russell, Nigel, Kerr, Kathleen F., Walter, Roland B., Dennis, Mike |
| Předmět: |
|
| Zdroj: |
Leukemia & Lymphoma; Jan2023, Vol. 64 Issue 1, p250-252, 3p |
| Abstrakt: |
The MRC/NCRI cohort included 9% patients with high-risk MDS, while the SWOG trials only enrolled AML patients. While, overall, AML has remained difficult to cure, the likelihood of resistance to treatment and/or treatment-related mortality varies greatly across individual patients. To the Editor Regulatory approval of several new drugs has expanded the therapeutic options for adults with acute myeloid leukemia (AML) [[1], [3]]. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
